Doxil filed in US for breast cancer
This article was originally published in Scrip
Executive Summary
Ortho Biotech (Johnson & Johnson) has filed a supplemental new drug application (sNDA) with the US FDAfor the use of its chemotherapy drug Doxil (doxorubicin HCl liposome injection) to treat advanced breast cancer.